| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
|
Nat Genet
|
2009
|
14.16
|
|
2
|
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.
|
Dig Dis
|
2011
|
3.74
|
|
3
|
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
|
Hepatology
|
2013
|
3.27
|
|
4
|
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.
|
Hepatology
|
2011
|
3.00
|
|
5
|
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
|
Hepatology
|
2014
|
2.83
|
|
6
|
Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.
|
Liver Transpl
|
2014
|
2.77
|
|
7
|
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
|
Hepatology
|
2013
|
1.81
|
|
8
|
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
|
J Hepatol
|
2010
|
1.80
|
|
9
|
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.
|
J Hepatol
|
2005
|
1.74
|
|
10
|
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.
|
Hepatology
|
2006
|
1.60
|
|
11
|
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.
|
Hepatol Res
|
2010
|
1.58
|
|
12
|
Branched-chain amino acids as pharmacological nutrients in chronic liver disease.
|
Hepatology
|
2011
|
1.52
|
|
13
|
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.
|
Hepatology
|
2010
|
1.44
|
|
14
|
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.
|
PLoS One
|
2012
|
1.44
|
|
15
|
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma.
|
J Hepatol
|
2006
|
1.40
|
|
16
|
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.
|
Hum Mol Genet
|
2011
|
1.31
|
|
17
|
Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey.
|
Ann Surg
|
2014
|
1.25
|
|
18
|
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
|
Oncology
|
2011
|
1.24
|
|
19
|
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).
|
Hepatol Res
|
2015
|
1.23
|
|
20
|
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
|
J Viral Hepat
|
2014
|
1.23
|
|
21
|
Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.
|
J Hepatol
|
2012
|
1.19
|
|
22
|
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
|
Hepatology
|
2011
|
1.19
|
|
23
|
Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.
|
J Clin Microbiol
|
2007
|
1.14
|
|
24
|
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.
|
Hepatol Res
|
2010
|
1.13
|
|
25
|
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
|
J Hepatol
|
2011
|
1.09
|
|
26
|
Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy.
|
J Gastroenterol
|
2013
|
1.07
|
|
27
|
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.
|
Oncology
|
2014
|
1.06
|
|
28
|
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
|
Liver Int
|
2014
|
1.05
|
|
29
|
T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection.
|
Clin Infect Dis
|
2005
|
1.02
|
|
30
|
Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study.
|
Gen Hosp Psychiatry
|
2003
|
1.01
|
|
31
|
Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease.
|
J Gen Virol
|
2003
|
1.00
|
|
32
|
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
|
Cancer
|
2013
|
1.00
|
|
33
|
Liver Cancer Working Group report.
|
Jpn J Clin Oncol
|
2010
|
1.00
|
|
34
|
Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.
|
Hepatol Res
|
2014
|
1.00
|
|
35
|
Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.
|
J Clin Microbiol
|
2009
|
0.98
|
|
36
|
Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.
|
Dig Dis Sci
|
2013
|
0.98
|
|
37
|
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.
|
J Gastroenterol
|
2014
|
0.98
|
|
38
|
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.
|
J Gastroenterol
|
2009
|
0.97
|
|
39
|
Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients.
|
J Gastroenterol
|
2013
|
0.96
|
|
40
|
Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update.
|
Oncology
|
2014
|
0.96
|
|
41
|
A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients.
|
Ann Surg
|
2015
|
0.94
|
|
42
|
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
|
J Med Virol
|
2011
|
0.94
|
|
43
|
No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.
|
BMC Med Genet
|
2012
|
0.94
|
|
44
|
Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens.
|
J Hepatol
|
2003
|
0.94
|
|
45
|
A case of primary leiomyoma of the liver in a patient without evidence of immunosuppression.
|
Hepatol Res
|
2002
|
0.92
|
|
46
|
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
|
Antivir Ther
|
2011
|
0.91
|
|
47
|
Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.
|
J Hepatol
|
2011
|
0.91
|
|
48
|
Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy.
|
J Gastroenterol Hepatol
|
2005
|
0.91
|
|
49
|
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.
|
Hepatol Res
|
2010
|
0.91
|
|
50
|
[High-sensitivity C-reactive protein (hs-CRP): a promising biomarker for the screening of non-alcoholic steatohepatitis (NASH)].
|
Nihon Rinsho
|
2006
|
0.90
|
|
51
|
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
|
Antivir Ther
|
2014
|
0.89
|
|
52
|
Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers.
|
J Gastroenterol
|
2012
|
0.89
|
|
53
|
Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.
|
Ann Surg
|
2014
|
0.88
|
|
54
|
The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
|
J Hepatol
|
2008
|
0.88
|
|
55
|
Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
|
J Gastroenterol
|
2013
|
0.88
|
|
56
|
Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.
|
Oncology
|
2011
|
0.87
|
|
57
|
Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells.
|
J Infect Dis
|
2003
|
0.87
|
|
58
|
2011 Japanese Society for Dialysis Therapy guidelines for the treatment of hepatitis C virus infection in dialysis patients.
|
Ther Apher Dial
|
2012
|
0.87
|
|
59
|
Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.
|
Gastroenterology
|
2008
|
0.87
|
|
60
|
Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.
|
Hepatol Int
|
2010
|
0.87
|
|
61
|
Changes of HCV quasispecies during combination therapy with interferon and ribavirin.
|
Hepatol Res
|
2004
|
0.87
|
|
62
|
Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.
|
Br J Clin Pharmacol
|
2003
|
0.86
|
|
63
|
Quantification of collagen and elastic fibers using whole-slide images of liver biopsy specimens.
|
Pathol Int
|
2013
|
0.86
|
|
64
|
Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan.
|
Intern Med
|
2013
|
0.86
|
|
65
|
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
|
J Gastroenterol
|
2014
|
0.84
|
|
66
|
A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
|
Hepatol Res
|
2013
|
0.84
|
|
67
|
Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.
|
Oncology
|
2013
|
0.84
|
|
68
|
Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.
|
J Gastroenterol
|
2010
|
0.84
|
|
69
|
Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009.
|
Hepatol Res
|
2010
|
0.84
|
|
70
|
Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging.
|
Hepatol Res
|
2014
|
0.84
|
|
71
|
Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.
|
World J Gastroenterol
|
2013
|
0.84
|
|
72
|
Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
|
J Gastroenterol
|
2014
|
0.83
|
|
73
|
Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography.
|
Hepatol Res
|
2003
|
0.83
|
|
74
|
Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy.
|
Hepatol Res
|
2003
|
0.82
|
|
75
|
Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C.
|
J Hepatol
|
2003
|
0.82
|
|
76
|
Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.
|
Hepatol Res
|
2010
|
0.82
|
|
77
|
LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients.
|
Hepatology
|
2012
|
0.82
|
|
78
|
Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan.
|
Hepatol Res
|
2006
|
0.81
|
|
79
|
Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
|
J Med Virol
|
2011
|
0.81
|
|
80
|
Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.
|
Antivir Ther
|
2012
|
0.81
|
|
81
|
Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients.
|
Hepatol Res
|
2013
|
0.81
|
|
82
|
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.
|
J Gastroenterol
|
2011
|
0.81
|
|
83
|
Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
|
BMC Infect Dis
|
2012
|
0.81
|
|
84
|
Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.
|
Intervirology
|
2005
|
0.80
|
|
85
|
Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
|
J Med Virol
|
2013
|
0.80
|
|
86
|
Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.
|
Hepatol Res
|
2004
|
0.80
|
|
87
|
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.
|
J Gastroenterol
|
2014
|
0.80
|
|
88
|
Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.
|
Hepatol Res
|
2011
|
0.79
|
|
89
|
Case-control study for the identification of virological factors associated with fulminant hepatitis B.
|
Hepatol Res
|
2009
|
0.79
|
|
90
|
Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy.
|
Hepatol Res
|
2013
|
0.79
|
|
91
|
Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.
|
Hepatol Res
|
2009
|
0.78
|
|
92
|
Laparoscopic radiofrequency ablation for hepatocellular carcinoma.
|
Dig Endosc
|
2009
|
0.78
|
|
93
|
Reply: To PMID 23564522.
|
Hepatology
|
2014
|
0.78
|
|
94
|
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.
|
Hepatol Res
|
2010
|
0.78
|
|
95
|
Demonstration of quality of care measurement using the Japanese liver cancer registry.
|
Hepatol Res
|
2011
|
0.78
|
|
96
|
Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey.
|
Ann Surg
|
2014
|
0.78
|
|
97
|
[Long time oral supplementation with branched-chain amino acids improves survival and decreases recurrences in patients with hepatocellular carcinoma].
|
Nihon Shokakibyo Gakkai Zasshi
|
2008
|
0.78
|
|
98
|
Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.
|
Hepatol Res
|
2011
|
0.78
|
|
99
|
Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
|
J Hepatobiliary Pancreat Sci
|
2014
|
0.78
|
|
100
|
External validation of FIB-4: diagnostic accuracy is limited in elderly populations.
|
Hepatology
|
2008
|
0.77
|
|
101
|
Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
|
Clin Drug Investig
|
2012
|
0.77
|
|
102
|
Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts.
|
Hepatol Res
|
2008
|
0.77
|
|
103
|
Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model.
|
Biosystems
|
2009
|
0.77
|
|
104
|
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.
|
J Gastroenterol
|
2011
|
0.77
|
|
105
|
Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey.
|
Dig Dis
|
2014
|
0.77
|
|
106
|
Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study.
|
Oncology
|
2014
|
0.77
|
|
107
|
Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.
|
Hepatol Res
|
2014
|
0.77
|
|
108
|
Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
|
Ther Apher Dial
|
2014
|
0.76
|
|
109
|
Pegylated interferon-associated retinopathy in chronic hepatitis C patients.
|
Jpn J Ophthalmol
|
2006
|
0.76
|
|
110
|
A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan.
|
Hepatol Int
|
2009
|
0.76
|
|
111
|
Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm.
|
Liver Int
|
2013
|
0.75
|
|
112
|
Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
|
J Med Virol
|
2013
|
0.75
|
|
113
|
Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
|
PLoS One
|
2016
|
0.75
|
|
114
|
Is the incidence of intrahepatic multicentric recurrence of hepatocellular carcinoma more frequent in "the carcinogenic stage" than in liver cirrhosis?
|
J Gastroenterol
|
2003
|
0.75
|
|
115
|
The interferon sensitivity determining region in the era of combination therapies and the rational use of such therapies for patients with HCV genotype 1b infection.
|
Gastroenterology
|
2003
|
0.75
|
|
116
|
Reply: To PMID 24734314.
|
Liver Transpl
|
2014
|
0.75
|
|
117
|
Tolvaptan for the Treatment of Refractory Ascites.
|
Intern Med
|
2016
|
0.75
|
|
118
|
Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
|
J Gastroenterol Hepatol
|
2014
|
0.75
|
|
119
|
Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection.
|
Virology
|
2003
|
0.75
|
|
120
|
[Epithelioid hemangioendothelioma of the liver diagnosed by laparoscopy guided biopsy].
|
Nihon Shokakibyo Gakkai Zasshi
|
2008
|
0.75
|
|
121
|
[Hepatitis B viral mutation and its clinical significance].
|
Nihon Rinsho
|
2004
|
0.75
|
|
122
|
[Antiviral effect of carnitine for chronic hepatitis or liver cirrhosis patients].
|
Nihon Rinsho
|
2015
|
0.75
|
|
123
|
Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B.
|
Hepatol Res
|
2012
|
0.75
|
|
124
|
[Ulcerative colitis developed after acute exacerbation of chronic hepatitis B].
|
Nihon Naika Gakkai Zasshi
|
2002
|
0.75
|
|
125
|
Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.
|
Intervirology
|
2014
|
0.75
|
|
126
|
[Treatment for hepatitis C under hemodialysis].
|
Nihon Rinsho
|
2015
|
0.75
|
|
127
|
[A case of systemic amyloidosis with cholangiectasis diagnosed by liver biopsy].
|
Nihon Shokakibyo Gakkai Zasshi
|
2013
|
0.75
|
|
128
|
Imaging diagnosis and molecular profiling of hepatocellular carcinoma.
|
Nihon Shokakibyo Gakkai Zasshi
|
2016
|
0.75
|
|
129
|
Management of ascites in cirrhotic patients.
|
Nihon Shokakibyo Gakkai Zasshi
|
2017
|
0.75
|
|
130
|
[A case of advanced gastric cancer acquired long-term response two years or more by treatment with oral anticancer drug TS-1].
|
Gan To Kagaku Ryoho
|
2004
|
0.75
|
|
131
|
[A triple combination therapy of simeprevir (SM), pegylated-interferon and ribavirin (PR) with chronic hepatitis C virus genotype 1 infection].
|
Nihon Rinsho
|
2015
|
0.75
|
|
132
|
Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers.
|
Hepatol Res
|
2013
|
0.75
|
|
133
|
Optimal timing of interferon treatment for acute hepatitis C.
|
Hepatol Res
|
2005
|
0.75
|
|
134
|
[Prediction of response to peg-interferon plus ribavirin therapy for chronic hepatitis C].
|
Nihon Shokakibyo Gakkai Zasshi
|
2011
|
0.75
|
|
135
|
Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
|
Dig Dis
|
2012
|
0.75
|
|
136
|
[Combination therapy of interferon plus ribavirin for chronic hepatitis C].
|
Nihon Rinsho
|
2004
|
0.75
|
|
137
|
Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
|
Gan To Kagaku Ryoho
|
2010
|
0.75
|
|
138
|
[Noninvasive Estimation of Liver Fibrosis and Hepatocellular Carcinoma Development Using WFA(+)-M2BP in Chronic Hepatitis C Patients].
|
Rinsho Byori
|
2015
|
0.75
|
|
139
|
Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey.
|
Ann Surg
|
2017
|
0.75
|
|
140
|
[A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].
|
Nihon Rinsho
|
2015
|
0.75
|
|
141
|
Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease.
|
Dig Dis
|
2017
|
0.75
|
|
142
|
Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C.
|
Hum Genet
|
2014
|
0.75
|
|
143
|
Issues in need for a solution among patients with successful eradication of hepatitis C virus.
|
Nihon Shokakibyo Gakkai Zasshi
|
2016
|
0.75
|
|
144
|
Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients.
|
Hepatol Res
|
2005
|
0.75
|
|
145
|
[Prediction of response to peginterferon and ribavirin therapy for chronic hepatitis C analyzed by data mining method].
|
Nihon Rinsho
|
2011
|
0.75
|
|
146
|
[Analysis of replicating hepatitis C virus quasispecies in hepatocellular carcinoma tissues].
|
Nihon Rinsho
|
2004
|
0.75
|